Literature DB >> 16415308

Natural history of multiple sclerosis: a unifying concept.

Christian Confavreux1, Sandra Vukusic.   

Abstract

Multiple sclerosis can follow very different patterns of evolution and variable rates of disability accumulation. This raises the issue whether it represents one or several distinct diseases. We assessed demographic and clinical characteristics in 1844 patients with multiple sclerosis that we categorized according to the classification of Lublin and Reingold (1996) into 1066 (58%) relapsing-remitting, 496 (27%) secondary progressive, 109 (6%) progressive relapsing and 173 (9%) primary progressive cases of multiple sclerosis. Relapsing-remitting and secondary progressive cases shared similar age at disease onset (median = 28.7 versus 29.5 years; P = 0.21), initial symptoms of the relapsing-remitting phase, degree of recovery from the first neurological episode, and time from the first to the second episode. By contrast, disease duration was twice as long in secondary progressive than in relapsing-remitting cases (mean +/- SD = 17.6 +/- 9.6 versus 8.7 +/- 8.6 years; P < 0.001). Progressive relapsing and primary progressive cases were essentially similar in their clinical characteristics. In patients experiencing a progressive course, median age at onset of progressive phase was similar in secondary progressive cases and in cases who were progressive from onset (39.1 versus 40.1 years; P = 0.47). The proportion of cases with superimposed relapses during progression was approximately 40% in both categories. Finally, the 1562 patients with an exacerbating-remitting initial course and the 282 patients with a progressive initial course of the disease were essentially similar with respect to the time course of disability accumulation from assignment to a given disability score, and the age at assignment of disability landmarks. These observational data suggest that the clinical phenotype and course of multiple sclerosis are age dependent. Relapsing-remitting disease can be regarded as multiple sclerosis in which insufficient time has elapsed for the conversion to secondary progression; secondary progressive forms as relapsing-remitting multiple sclerosis that has 'grown older'; and progressive from onset cases as multiple sclerosis 'amputated' from the usual preceding relapsing-remitting phase. Times to reach disability milestones, and ages at which these landmarks are reached, follow a predefined schedule not obviously influenced by relapses, whenever they may occur, or by the initial course of the disease, whatever its phenotype. This leads to a unifying concept of the disease in which primary and secondary progression might be regarded as essentially similar. From the clinical and statistical positions, multiple sclerosis might be considered as one disease with different clinical phenotypes rather than an entity encompassing several distinct diseases-the position of complexity rather than true heterogeneity.

Entities:  

Mesh:

Year:  2006        PMID: 16415308     DOI: 10.1093/brain/awl007

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  166 in total

1.  Relapses and disability accumulation in progressive multiple sclerosis.

Authors:  M Mateo Paz Soldán; Martina Novotna; Nuhad Abou Zeid; Nilufer Kale; Melih Tutuncu; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; B Mark Keegan; Istvan Pirko; Sean J Pittock; Claudia F Lucchinetti; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci
Journal:  Neurology       Date:  2014-11-14       Impact factor: 9.910

Review 2.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

3.  Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study).

Authors:  O Fernández; V Fernández; T Arbizu; G Izquierdo; I Bosca; R Arroyo; J A García Merino; E de Ramón
Journal:  J Neurol       Date:  2010-04-10       Impact factor: 4.849

4.  Multiple sclerosis affects the frequency content in the vertical ground reaction forces during walking.

Authors:  Shane R Wurdeman; Jessie M Huisinga; Mary Filipi; Nicholas Stergiou
Journal:  Clin Biomech (Bristol, Avon)       Date:  2010-10-29       Impact factor: 2.063

5.  Aggregation of multiple sclerosis genetic risk variants in multiple and single case families.

Authors:  Pierre-Antoine Gourraud; Joseph P McElroy; Stacy J Caillier; Britt A Johnson; Adam Santaniello; Stephen L Hauser; Jorge R Oksenberg
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

Review 6.  [Clinically isolated syndrome].

Authors:  M Platten; T Lanz; M Bendszus; R Diem
Journal:  Nervenarzt       Date:  2013-10       Impact factor: 1.214

7.  [Retrovirus superantigen hypothesis of multiple sclerosis].

Authors:  A Emmer; M S Staege; M E Kornhuber
Journal:  Nervenarzt       Date:  2013-10       Impact factor: 1.214

Review 8.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

9.  Randomized controlled trial of physical activity, cognition, and walking in multiple sclerosis.

Authors:  Brian M Sandroff; Rachel E Klaren; Lara A Pilutti; Deirdre Dlugonski; Ralph H B Benedict; Robert W Motl
Journal:  J Neurol       Date:  2013-12-10       Impact factor: 4.849

10.  Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France.

Authors:  M Debouverie; S Louis; S Pittion-Vouyovitch; T Roederer; H Vespignani
Journal:  J Neurol       Date:  2007-06-25       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.